AROMA-BIT
23.7.2019 03:32:07 CEST | Business Wire | Press release
Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/
Aroma Bit: http://www.aromabit.com
Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size
Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Microbalance type sensor substrate, which demonstrates ultra-high sensitivity in the sensor market. However, further size reduction, cost reduction to meet high volume application market, such as smartphone, was challenging with conventional QCM type smell sensor.
With the newly developed silicon CMOS type smell sensor, ultra-compact, high smell resolution and low cost can be realized, to be embedded to system such as smartphone or IoT devices. For instance, it is expected that resolution equivalent to dog nose’s resolution (roughly 1,200 receptors) within 1mm die size can be achieved using the new type of sensor substrate.
With new addition of sensor substrate technology, Aroma Bit now holds two types of sensor substrate technology line up: (1) conventional and yet ultra-high sensitivity QCM type sensor substrate technology, and (2) ultra-high resolution, ultra-compact, low cost silicon CMOS type sensor substrate technology. Combined, highly competitive sensor technology portfolio is realized in two key performance for smell sensor, namely, sensor sensitivity and smell resolution. As a result, the addition of the new sensor is expected to further enhances Aroma Bit’s technology competitive advantage against its competitors in the compact smell sensor space.
Aroma Bit is currently also accelerating its development of digital smell database or smell big-data based on its hardware competitive advantage. Sensor hardware and smell database together, Aroma Bit is committed to retain its top-position in growing digital olfactory market, thereby realizing Aroma Bit’s vision “to realize a better world by visualizing the world of smell/aroma through odor imaging technology.”
New subsidiary certified as the first Toyohashi University of Technology University- Launched Venture Company
The new developed subsidiary, Aroma Bit Silicon Sensor Technology, Inc., is certified as the first Toyohashi University of Technology certified University-Launch Venture Company.
While University-Launched Venture company is on the rise in Japan, there is limited successful case leading to industrialization, due to factors such as lack of intellectual property conflict among large companies interest, skill set mismatch on researcher as entrepreneurs, among others.
In this particular Industry-academia collaboration case, the chance to commercialize technology is expected to increase by assigning venture company a role to drive business development of the technology developed jointly with university.
Background:
Aroma Bit succeeded in developing next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact and high resolution by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology.
In 2017, Toyohashi Technology of University, Toyohashi Sensor Kyogikai Corporation, Hamamatsu Photonics K.K., Toho Technology Corporation, Nippon Chemi-con Corporation and Aroma Bit together formed private Consortium COSCo (CMOS Odor Sensor Consortium). In 2018, COSCo consortium released working prototypes such as Kaori-Camera (Aroma Camera) and i-sniffer.
In the interest to aggregate the achievement from COSCo consortium and further accelerate development and industrialization, Aroma Bit Silicon Sensor Technology, Inc. (Hereafter, “ABSST”) is founded as Aroma Bit’s subsidiary.
Going forward, ABSST is committed to develop the silicon CMOS type next generation smell sensor that are ultra-high resolution, ultra-compact and low-cost embeddable to smartphone and IoT Devices.
New Subsidiary Company Profile |
|
Name of company: |
Aroma Bit Silicon Sensor Technology Inc. (ABSST) |
Date of Registration: |
June 28th, 2019 |
Paid-in-Capital: |
10 Million JPY [Aroma Bit, Inc. Subsidiary] |
Business Profile: |
Planning, Development, Manufacturing and Sales of silicon CMOS based next generation smell, gas sensor, and other related business |
Representative Management: |
Representative Director & CEO Shunichiro Kuroki [Current Representative Director & CEO of Aroma Bit, Inc.] |
Address: |
E205 KSP 3-2-1 Sakado, Takatsu-ku, Kawasaki-city, Kanagawa 213-0012 [Aroma Bit Kawasaki Lab] |
Corporate URL: |
|
Contact: |
Email: info@aromabitsst.com
|
About Aroma Bit |
Aroma Bit develops, produces and sells electronic equipments and systems including compact odor imaging sensors. |
[Corporate summary] |
|
Name: |
Aroma Bit, Inc. |
Address: |
Sagami Building 2F 7-13-6 Ginza, Chuo-ku, Tokyo |
Representative: |
Representative Director & CEO Sunichiro Kuroki |
Established: |
February, 2014 |
Business: |
- Development, Production and Sales of electronic equipments and systems including compact odor imaging sensors. |
- Development, Production and Sales of innovative services using the Sensor products. |
|
|
- Other business related to the above. |
Corporate URL: |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
